---
title: "Bluebird Bio (BLUE.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/BLUE.US.md"
symbol: "BLUE.US"
name: "Bluebird Bio"
industry: "生物技術"
---

# Bluebird Bio (BLUE.US)

| Item | Detail |
|------|--------|
| Industry | 生物技術 |

## Company Profile

bluebird bio, Inc.是一家生物技術公司，專注于研究、開發和商業化基因療法，以治療美國的嚴重遺傳疾病。該公司針對嚴重遺傳疾病的產品候選包括 ZYNTEGLO（betibeglogene autotemcel），用于治療依賴輸血的β-地中海貧血；LYFGENIA（lovotibeglogene autotemcel），用于治療鐮狀細胞病（SCD）及有血管阻塞事件歷史的患者；以及 SKYSONA（elivaldogene autotemcel），用于治療腦部腎上腺白質營養不良。其臨床開發項目包括 HGB-205、HGB-206 和 HGB-210，評估 lovo-cel 在治療 SC...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-20T04:30:13.000Z

**Overall: D (0.62)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 362 / 403 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 127.51% |  |
| Net Profit YoY | 33.48% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 0.00 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 0.00 |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 103.95M |  |


**Multi Score**: D

#### Profit Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -546.54% | E |
| Profit Margin | -192.39% | E |
| Gross Margin | 68.39% | A |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 127.51% | A |
| Net Profit YoY | 33.48% | B |
| Total Assets YoY | -53.13% | E |
| Net Assets YoY | -144.16% | E |

#### Cash Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -51.98% | D |
| OCF YoY | 127.51% | A |

#### Operating Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.22 | D |

#### Debt Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 119.55% | E |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Bluebird Bio",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-546.54%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-192.39%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "68.39%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "127.51%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "33.48%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-53.13%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-144.16%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "B",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-51.98%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "127.51%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "D",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.22",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "E",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "119.55%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | ADMA生物制藥 (US.ADMA) | A | A | A | B | B | A |
| 02 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 03 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 04 | Rigel制藥 (US.RIGL) | A | A | A | C | B | A |
| 05 | OpGen (US.OPGN) | B | A | A | A | B | A |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.24 | 116/604 | - | - | - |
| PB | -0.84 | 535/604 | - | - | - |
| PS (TTM) | 0.47 | 21/604 | 0.47 | 0.47 | 0.47 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 4.97 |
| Highest Target | 8.00 |
| Lowest Target | 8.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/BLUE.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/BLUE.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/BLUE.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
